Taficita Tablet is a fixed-dose combination antiretroviral medication used primarily for the treatment and prevention of HIV infection.

Brand Name: Taficita

Composition: Emtricitabine, Tenofovir Alafenamide

Mechanism of Action:
Emtricitabine: Prevents viral RNA from being converted to DNA by inhibiting the reverse transcriptase enzyme. Like emtricitabine, tenofovir alafenamide works against HIV by blocking the virus's ability to replicate by inhibiting reverse transcriptase.

Uses:

HIV Infection

Dosage and Administration:

One tablet taken once a day, with or without food, is the usual dosage.

Side Effects:

·       Fatigue

·       Headache

·       Nausea

·       Vomiting

·       Fever

·       Cough

·       Insomnia

·       Liver Function Abnormalities

·       Allergic Reactions

Safety Advise:

Kidney  

Monitor kidney function regularly, as Taficita can cause nephrotoxicity. Kindly speak with your healthcare provider.

Liver  

Monitor liver function regularly, as Taficita can cause liver impairement. Kindly speak with your healthcare provider.

Pregnancy  

Taficita should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Taficita while nursing is most likely dangerous. Kindly speak with your healthcare provider.

Alcohol  

Taficita should not be taken with alcohol. Kindly speak with your healthcare provider.

Storage:

Store Taficita Tablet at a temperature between 15°C and 30°C (59°F to 86°F). Keep the tablets in the original packaging to protect them from light and moisture. Keep out of reach of children.

Refereences:

1.     Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018 Nov;78(17):1817-28.

2.     Ambrosioni J, Rojas Liévano J, Berrocal L, Inciarte A, de la Mora L, González-Cordón A, Martínez-Rebollar M, Laguno M, Torres B, Ugarte A, Chivite I. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. Journal of Antimicrobial Chemotherapy. 2022 Apr 1;77(4):1133-9.

3.     Squillace N, Ricci E, Maggi P, Taramasso L, Menzaghi B, De Socio GV, Piconi S, Maurizio Celesia B, Orofino G, Sarchi E, Pellicanò GF. Real-life safety of emtricitabine/tenofovir alafenamide/bictegravir. PLoS One. 2023 Aug 9;18(8):e0289132.

Disclaimer:

The main goal of Apothecare is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details:

Name: Mylan Pharmaceuticals Pvt Ltd - A Viatris Company

Address: Mylan Pharmaceuticals Private Limited , Commercial Operations , Prestige Tech Park,Platina-3, 7th to 12th floor, Prestige Tech Park, Kadubesanahalli, Bangalore -560103

Country of origin: India